You are currently viewing Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

This Week:

  • ❔ Mydecine CEO Downplays Concern Over Large Insider Activity and Late Filings
  • 🏫 UC Davis Scores $2.7m from NIDA to Explore Non-hallucinogenic Psychedelics
  • ⚖️ Oregon Health Authority Adopts Products, Testing and Training Rules

and more…

Psychedelic Sector News

Mydecine CEO Downplays Concern Over Large Insider Activity and Late Filings

On Tuesday, Mydecine’s CEO, David Joshua Bartch (who generally goes by ‘Josh Bartch’), filed more than 10 insider transaction notices, the earliest of which refers to a transaction that occurred in February 2020: over two years ago.

Note: According to the BC Securities Commission, insiders must file insider reports “within five days after trading the company’s securities.” A control person must file within three calendar days, meanwhile. “According to the System for Electronic Disclosure by Insiders’ (SEDI) documentation, “late filing or non-filing of insider reports is an offence under securities laws and may be subject to legal action.” But, according to the same document, the consequence for late filing of an insider report in British Columbia is just $50 per transaction, per insider, per issuer.

The number of shares involved in these transactions is by no means insignificant, with one filing showing a May 2021 private transfer of 10,000,000 shares from Bartch to an unknown counterparty. In November 2021, Bartch received over 5 million shares as compensation.

We asked Bartch about these transactions, which were reported incredibly late. Bartch confirmed that “these are NOT sales of stock but private transfers,” to which he “did not receive proceeds” (emphasis his own).

Bartch went on to explain that he has “made zero public market stock sales,” and that he has “no intention of doing so in the near term.”

Still, the unexplained and large transfer of shares is odd, and warrants scrutiny; especially given that incredibly late insider filings. We asked Bartch to provide more information, such as disclosing the counterparty or the purpose of the transfer, but the CEO refused to provide further comment.

“I will be doing a few interviews in the near future addressing this, Bartch told us. He said that he also intends to clarify “the reasoning for the reverse split, several very positive company updates and the numerous false statements circulated in chat rooms.”

Today, the company announced the closing of a $2.8m public offering, paying a 7% commission to agents. The company is running on fumes, with a monthly burn of $1.6m according to accounts for the quarter ended March 31. During that quarter, the company spent $2m on salaries and consulting fees.

UC Davis Scores $2.7m from NIDA to Explore Non-hallucinogenic Psychedelics

Researchers at the University of California, Davis and the University of Colorado Anschutz Medical Campus have scored a $2.7m grant from the National Institute on Drug Abuse (NIDA).

David Olson, founder of Delix Therapeutics, is heading-up the work. Talking about these non-hallucinogenic psychedelic analogs (or, ‘psychoplastogens’, as he prefers to call them) Olson said that the grant “will help us to understand the basic mechanisms by which these compounds impact addiction, and hopefully develop more effective and better tolerated treatments.”

The press release from UC Davis makes it clear that Delix is not involved in this project.

Oregon Health Authority Adopts Products, Testing and Training Rules

Last Friday, the Oregon Health Authority (OHA) released a set of rules that will govern products, testing and training programs for the state’s therapeutic psilocybin program set to launch next January.

Given the adoption of these rules, Oregon Psilocybin Services should be in a position to begin accepting training program applications from June. As noted previously, rules governing products and manufacturing stipulate that only one species of mushroom is permitted, Psilocybe cubensis.

The remainder of the rules will be considered in autumn and adopted by the end of the calendar year.

Yesterday, the Advisory Board rejected a set of recommendations regarding “Privileges and Duties of Entheogenic Practitioners,” which sought to provide protections for the religious use of psilocybin. The protections and considerations would effectively have created a separate category of licensure, with lesser standards.

The Advisory Board had initially supported such protections, but on Wednesday Oregon’s Department of Justice issued a legal opinion stating clearly that the OHA has “no statutory authority… to exempt anyone engaged in the manufacturing, delivery or possession of psilocybin from licensure and licensure is the only mechanism for being exempt from state criminal liability.” You can read the full set of responses here.

Atai CEO Included in List of 15 Highest-Paid CEOs in Biopharma

This week, Business Insider looked at the 15 highest-paid CEOs in biopharma.

The list included atai Life Sciences’ Florian Brand. According to Insider, Brand’s 2021 pay package was $26.5m which includes “$21 million in stock awards and $4.6 million in options”.

See the full list at Business Insider.

Featured Psychedelic Jobs

Browse more roles and get more job posts to your inbox by signing up for alerts here.

Weekend Reading

Free Event: “Mapping the Future of Psychedelics: Deconstructing Powerful Drugs to Make Better Medicine”

Stanford’s Boris Heifets is giving a free webinar on June 22nd that will cover:

  • Limitations of receptor-based drug development
  • Our approach to “circuit-based” therapeutic discovery
  • Recent clinical findings on the relationship between anaesthetic states and recovery from mood and stress disorders

More info, and registration, here.

“Hope and hype: psychedelic drugs still to prove value in clinical trials”

This article from Clinical Trials Arena identifies a number of key issues facing psychedelic research today, including:

  • Difficulties with blinding
  • Investigator biases
  • Overhyped expectations
  • Difficulties recruiting participants for certain indications (SUDs, eating disorders, etc.)
  • Strict inclusion criteria
  • A “high bar” to argue for rescheduling

Read the full piece here.

“Hot Psilocybin Patent Garbage”

From the patent on using LSD to treat food allergies to Compass’s attempt to patent psilocybin use and “soft furniture,” last week’s publication of the patent application entitled “Treatment of Anxiety and Depression” or the “NYU Application” officially marks a new race to the psychedelic patent bottom.

Read the full piece on Matt Zorn’s Substack.

Psychedelic Alpha Editor-at-Large Graham Pechenik caught wind of this patent application the day it published and Tweeted about the development:


Weekly Bulletins

Join our newsletter to have our Weekly Bulletin delivered to your inbox every Friday evening. We summarise the week’s most important developments and share our Weekend Reading suggestions.

Live Updates

Join us on Twitter for the latest news and analysis.

Other Channels

You can also find us on LinkedIn, Instragram, and Facebook.